|17th August 2020||Erin Jones||10,000||Exercise of derivative||$0.35||$3,450.00|
|21st August 2019||Raphael Rousseau||10,000||Exercise of derivative||$0.76||$7,600.00|
|21st August 2019||Raphael Rousseau||10,000||Open or private sale||$10.76||$107,631.00|
|29th January 2019||Erin Jones||10,000||Exercise of derivative||$0.35||$3,450.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Gritstone Oncology, Inc. is a clinical-stage biotechnology company. The company is developing the next generation of cancer immunotherapies to fight multiple cancer types.